If the current trials are successful, then Carmat will be able to continue its momentum and continue with artificial heart implantations. The tests in question concern two patient candidates currently being recruited. If their transplants are successful then the company will be able to enter its development phase by scheduling around twenty artificial heart transplants. Carmat “will be able to propose to the supervisory authorities, in France and in other countries, the protocol of a new study extended to about twenty patients followed in the longer term such as, for example, 180 days”, announces the group. This stage would start six months behind schedule.
the first patient to benefit from a heartartificial Carmat, on December 18, 2013, died 75 days after the transplant at the Georges-Pompidou hospital, in Paris. 75 days was much more than the 30 days set to confirm the success of the test. The team of doctors hoped for a survival of one month. The 76-year-old patient suffered from heart failure (a heart failure whereby the heart can no longer pump enough blood to meet the body’s needs).
No information on the state of health of the second patient
This artificial heart implantation was presented as a world first. Carrying many hopes, it could become an “alternative to heart transplantation, too rarely available for the millions of people with heart failure around the world”, then explained the Assistance Publique-Hôpitaux de Paris (AP-HP).
a second patient received an artificial heart last August 5 at the Nantes University Hospital.
The implantation of this prosthesis received less publicity. According to the latest news, the second candidate to be transplanted is doing well, according to his surgeon. One thing is certain: if his artificial heart has already beaten 77 days, that is to say 3 days more than for the first implanted heart.
